



(51) International Patent Classification:

C12N 15/00 (2006.01) C12P 19/28 (2006.01)
C12P 19/08 (2006.01)

(21) International Application Number:

PCT/US2014/029897

(22) International Filing Date:

15 March 2014 (15.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/801,948 15 March 2013 (15.03.2013) US

(71) Applicant: GLYCOBIA, INC. [US/US]; 410 Weill Hall,
McGovern Center, Ithaca, NY 14853 (US).

(72) Inventors; and

(71) Applicants : MERRITT, Judith, H. [US/US]; C/o Glycobia, Inc., 410 Weill Hall, McGovern Center, Ithaca, NY 14853 (US). FISHER, Adam, C. [US/US]; C/o Glycobia, Inc., 410 Weill Hall, McGovern Center, Ithaca, NY 14853 (US). HAMILTON, Brian, S. [US/US]; C/o Glycobia, Inc., 410 Weill Hall, McGovern Center, Ithaca, NY 14853

(US). DELISA, Matthew, P. [US/US]; C/o Glycobia, Inc., 410 Weill Hall, McGovern Center, Ithaca, NY 14853 (US).

(74) Agent: HONG, Chang, B.; Glycobia, Inc., 410 Weill Hall,
McGovern Center, Ithaca, NY 14853 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: POLYSIALIC ACID, BLOOD GROUP ANTIGENS AND GLYCOPROTEIN EXPRESSION




FIG. 23

(57) Abstract: The invention described herein generally relates to glycoengineering host cells for the production of glycoproteins for therapeutic use. Host cells are modified to express biosynthetic glycosylation pathways. Novel prokaryotic host cells are engineered to produce N-linked glycoproteins wherein the glycoproteins comprise polysialic acid or blood group antigens.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, —
KM, ML, MR, NE, SN, TD, TG).

*before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*